Dynamic T1-weighted magnetic resonance imaging and positron emission tomography in patients with lung cancer: Correlating vascular physiology with glucose metabolism

被引:0
|
作者
Hunter, GJ
Hamberg, LM
Choi, N
Jain, RK
McCloud, T
Fischman, AJ
机构
[1] Massachusetts Gen Hosp, Dept Radiol, Ctr Imaging & Pharmaceut Res, Boston, MA 02129 USA
[2] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02129 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The management of primary lung cancer relies on sophisticated imaging methods to assist in the diagnosis, staging, and evaluation of tumor regression during treatment, The information provided is generally anatomical in nature, except for that provided by positron emission tomography with [F-18]fluorodeoxyglucose, a modality that yields physiological data that have been shown to be useful in identifying neoplasia, based on an elevated glucose metabolic rate, Because the metabolism of malignant tissue depends intimately on neovascularization to provide oxygen and glucose in sufficient quantities to allow tumor growth, the characterization of tumor vascular physiology could be an important tool for assessing and predicting the likely effectiveness of treatment, Our goal was to show the feasibility and practical value of parameters of tumor vascular physiology obtained using dynamic Tl-weighted magnetic resonance imaging (MRI), to correlate them with glucose metabolism and to demonstrate changes in these parameters during and after treatment in patients with lung cancer, Parameters of vascular physiology [permeability-surface area (PS) product and extracellular contrast agent distribution volume] and glucose metabolism were assessed in 14 patients with lung cancer, Glucose metabolism was measured by using [F-18]fluorodeoxyglucose-positron emission tomography. Vascular physiology was assessed by dynamic T1-weighted, contrast-enhanced MRI, The mean PS product in tumor was 0.0015 +/- 0.0002 s(-1) (n = 13) before, 0.0023 +/- 0.0003 s(-1) (n = 3, P = 0.053) midway through, and 0.00075 +/- 0.0002 s(-1) (n = 5, P < 0.03) 2 weeks after treatment, Values for the extracellular contrast distribution space were 0.321 +/- 0.03 before, 0.289 +/- 0.02 midway through, and 0.195 +/- 0.02 (P < 0.01) 2 weeks after therapy, The glucose metabolic rate was significantly correlated with the PS product (P < 0.01) but not with the extracellular contrast distribution space, Our results demonstrate that tumor PS product correlates with glucose metabolism, that chemo-and radiotherapy induce observable and quantifiable changes in these parameters, and that such changes can be measured by irt vivo dynamic MRI. Quantitative dynamic T1-weighted MRI of tumor vascular physiology may have a useful role in the clinical management of lung cancer.
引用
收藏
页码:949 / 955
页数:7
相关论文
共 50 条
  • [21] Dynamic contrast-enhanced magnetic resonance imaging of the kidney: Comparison of T1-weighted and T2*-weighted sequences
    Tsushima, Y
    Niemi, P
    Komu, M
    Dean, PB
    Haapanen, A
    Kormano, M
    ACADEMIC RADIOLOGY, 1996, 3 : S176 - S178
  • [22] Diet and gastrointestinal signal on T1-weighted magnetic resonance imaging of mice
    Kiryu, Shigeru
    Inoue, Yusuke
    Yoshikawa, Kohki
    Shimada, Mono
    Watanabe, Makoto
    Ohtomo, Kuni
    MAGNETIC RESONANCE IMAGING, 2010, 28 (02) : 273 - 280
  • [23] Visualisation of the fetal bowel on T1-weighted magnetic resonance imaging scans
    Hyde, G.
    Fry, A.
    Whitby, E.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2019, 126 : 84 - 84
  • [24] Multimodality Imaging of Pancreatic Cancer-Computed Tomography, Magnetic Resonance Imaging, and Positron Emission Tomography
    Raman, Siva P.
    Horton, Karen M.
    Fishman, Elliot K.
    CANCER JOURNAL, 2012, 18 (06): : 511 - 522
  • [25] Is diffusion-weighted magnetic resonance imaging superior to positron emission tomography with fludeoxyglucose F 18 in imaging non-small cell lung cancer?
    Ohba, Yasuomi
    Nomori, Hiroaki
    Mori, Takeshi
    Ikeda, Koei
    Shibata, Hidekatsu
    Kobayashi, Hironori
    Shiraishi, Shinya
    Katahira, Kazuhiro
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2009, 138 (02): : 439 - 445
  • [26] Positron emission tomography with computed tomography/magnetic resonance imaging for primary staging of prostate cancer
    Hasa, Ergela
    Langbein, Thomas
    Eiber, Matthias
    Knorr, Karina
    RADIOLOGE, 2021, 61 (09): : 818 - 824
  • [27] USE OF MAGNETIC-RESONANCE-IMAGING AND POSITRON EMISSION TOMOGRAPHY IN THE ASSESSMENT OF SYNOVIAL VOLUME AND GLUCOSE-METABOLISM IN PATIENTS WITH RHEUMATOID-ARTHRITIS
    POLISSON, RP
    SCHOENBERG, OI
    FISCHMAN, A
    RUBIN, R
    SIMON, LS
    ROSENTHAL, D
    PALMER, WE
    ARTHRITIS AND RHEUMATISM, 1995, 38 (06): : 819 - 825
  • [28] Diagnosis of symptomatic disc by magnetic resonance imaging: T2-weighted and gadolinium-DTPA-enhanced T1-weighted magnetic resonance imaging
    Yoshida, H
    Fujiwara, A
    Tamai, K
    Kobayashi, N
    Saiki, K
    Saotome, K
    JOURNAL OF SPINAL DISORDERS & TECHNIQUES, 2002, 15 (03): : 193 - 198
  • [29] Combining hyperpolarized magnetic resonance and positron emission tomography to interrogate prostate cancer metabolism
    Wang, Muxin
    Enriquez, Jose S.
    Dutta, Prasanta
    Han, Jenny
    Shepherd, Peter
    Frigo, Daniel
    Pisaneschi, Federica
    Bhattacharya, Pratip K.
    CANCER RESEARCH, 2024, 84 (06)
  • [30] Combining Positron Emission Tomography and Hyperpolarized Magnetic Resonance to Interrogate Prostate Cancer Metabolism
    Enriquez, Jose
    Dutta, Prasanta
    Armijo, Ryan
    Wang, Muxin
    Han, Jenny
    Shepherd, Peter
    Titus, Mark
    Frigo, Daniel
    Bhattacharya, Pratip
    Pisaneschi, Federica
    NUCLEAR MEDICINE AND BIOLOGY, 2023, 126 : S21 - S22